发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 68 |
| New Zealand | 23 |
| England | 21 |
| GERMANY (FED REP GER) | 20 |
| South Korea | 19 |
| Italy | 14 |
| Belgium | 13 |
| Spain | 13 |
| Netherlands | 12 |
| CHINA MAINLAND | 10 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| SPRINGER NATURE | 18 |
| PFIZER | 13 |
| KU LEUVEN | 11 |
| ERASMUS UNIVERSITY ROTTERDAM | 9 |
| HARVARD UNIVERSITY | 8 |
| CELLTRION INC | 6 |
| PEKING UNIVERSITY | 6 |
| UNIVERSITY OF CAMBRIDGE | 6 |
| CHINESE ACADEMY OF MEDICAL SCIENCES - P... | 5 |
| TIANJIN MEDICAL UNIVERSITY | 5 |
文章引用情况
1
Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease2
Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists3
Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries4
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence5
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1Biosimilar and Originator Infliximab in the Hospital Setting6
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial7
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab8
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2Biosimilar and Originator Etanercept in the Outpatient Setting9
Monoclonal Antibodies for Multiple Sclerosis: An Update10
Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study